US-based medical devices maker NanoVibronix has secured approval from Health Canada to sell its UroShield device in the country.
The WoundShield system is a patch-based therapeutic ultrasound device, which facilitates soft tissue regeneration and wound healing by using ultrasound to enhance local capillary perfusion and tissue oxygenation.
NanoVibronix CEO Brian Murphy said: “We believe that the Canadian market represents an attractive opportunity for our WoundShield system with more than 280 thousand patients suffering from persistent wounds, while diabetic foot ulcers are estimated to affect 25 percent of patients with diabetes.
“With chronic wounds affecting 5.7 million patients in the U.S., the total global wound device market is expected to reach $20 billion in 2016.
“WoundShield has also received a CE Mark for marketing clearance in Europe, where we are focusing on new sales and marketing initiatives.”
Last September, the firm also received Health Canada approval for its UroShield device, which avoids urinary tract infections (UTI) in patients with indwelling urinary catheters.
The UroShield system is a multi-targeting solution which was designed to work counter a number of factors that are essential in preventing catheter related complications.
Based in Elmsford of New York, NanoVibronix produces advanced technology to create low-frequency ultrasound waves that can be used in a range of medical applications.
The company also operates research and development center in Nesher, Israel.